This research aims to evaluate the effectiveness of MET-TKIs in NSCLC patients with the METex14 skipping mutation, particularly those with poor performance status.
Analyzed clinical activity of MET-TKIs in patients with METex14 mutation.
Focused on individuals categorized with poor performance status.
Assessed treatment outcomes in these patients.
Observed limited efficacy of MET-TKIs in patients with poor performance status.
Noted that effectiveness varies based on performance status.
Indicated potential for further study to improve treatment approaches.
Abstract
MET-TKIs are effective for NSCLC with the METex14 skipping mutation; however, their efficacy for patients with a poor PS is limited.